Standout Papers

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive ga... 2021 2026 2022 2024536
  1. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial (2023)
    Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet
  2. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826 (2023)
    Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology
  3. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (2021)
    Nicoletta Colombo, Coraline Dubot et al. New England Journal of Medicine

Immediate Impact

52 standout
Sub-graph 1 of 24

Citing Papers

Alzheimer’s Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review
2024 Standout
Dendritic Cells in Cancer Immunology and Immunotherapy
2024 Standout
3 intermediate papers

Works of Kan Li being referenced

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
2021 Standout
A prognostic model of Alzheimer's disease relying on multiple longitudinal measures and time‐to‐event data
2018

Author Peers

Author Last Decade Papers Cites
Kan Li 675 311 387 338 51 1.7k
Chun‐Chieh Wang 318 233 328 271 57 1.3k
Carin Y. Smith 382 231 405 157 67 2.2k
Chun‐Chieh Wang 326 425 417 634 80 1.9k
Karin S. Kapp 720 463 200 343 67 1.8k
Tara Barwick 316 510 304 256 88 1.9k
Lee-may Chen 792 208 255 289 42 1.6k
Susan A. Higgins 832 415 178 197 57 2.0k
Rakesh Gaur 873 209 93 206 39 1.6k
Anjali Gupta 567 222 221 73 54 1.9k
Gideon Zamba 437 237 206 130 42 1.2k

All Works

Loading papers...

Rankless by CCL
2026